Product Description
Mechanisms of Action: CD56 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pulmonary Blastoma|Neurofibrosarcoma|Rhabdomyosarcoma|Neuroblastoma|Synovial Sarcoma|Leukemia|Wilms Tumor|Small Cell Lung Cancer
Phase 1: Ovarian Cancer|Carcinoma, Merkel Cell|Multiple Myeloma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IMGN0005 | P1 |
Completed |
Multiple Myeloma |
2013-08-01 |
2019-03-19 |
Treatments |
|
| CDR0000491231 | P1 |
Completed |
Ovarian Cancer|Small Cell Lung Cancer|Carcinoma, Merkel Cell |
2011-10-01 |
2019-03-21 |
Treatments |
|
| IMGN901 | P1 |
Completed |
Multiple Myeloma |
2011-03-01 |
2019-03-21 |
||
| ADVL1522 | P2 |
Completed |
Neurofibrosarcoma|Wilms Tumor|Neuroblastoma|Synovial Sarcoma|Rhabdomyosarcoma|Pulmonary Blastoma |
2017-06-30 |
2022-01-14 |
Primary Endpoints |
|
| NCI-2015-00683 | P2 |
Completed |
Leukemia |
2017-06-06 |
2019-03-20 |
Treatments |
|
| 2010-022950-17 | P2 |
Completed |
Small Cell Lung Cancer |
2015-05-12 |
2022-03-13 |
Treatments |
|
| Immunogen 0007 | P2 |
Terminated |
Small Cell Lung Cancer |
2015-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| C10/IVB/001 | P2 |
Completed |
Small Cell Lung Cancer |
2008-11-01 |
2019-03-21 |
Treatments |